Dr. Can Cui focuses his practice on technology transactions, investments and intellectual property (IP) protection in the life sciences and med-tech industries, with a particular emphasis on cross-border deals involving Asia. His work encompasses technology licensing and acquisition, collaboration and strategic partnerships, joint ventures, and various forms of investment.
Can frequently represents life sciences and med-tech companies, from startups to multinational corporations, in worldwide and U.S.-China life sciences licensing and collaboration transactions, from target or drug discovery phase to clinical stage and beyond. His representation covers the entire value chain, and includes contract research, manufacture and supply, clinical trials, commercialization and distribution arrangements.
In the realm of private equity and venture capital, he regularly conducts IP due diligence and negotiates investment documentation for institutional and individual investors, and emerging and established life sciences and med-tech companies. Additionally, Can advises clients on IP aspects of mergers and acquisitions.
With his deep understanding of both China’s and U.S.’s regulatory landscapes, in connection with his cross-border transactional practice, Can provides guidance on China and U.S. IP laws, technology import and export regulations, cross-border investment restrictions, and data privacy laws and regulations. His wide-ranging experience in corporate matters, patent prosecution, and IP dispute resolution, combined with his scientific education, allows him to offer advice to life sciences and med-tech companies on a variety of legal issues they may face.
In his venture capital and emerging technology practice, Dr. Cui serves as an advisor to life sciences startup companies accelerated by H7 BioCapital and works with them 1:1 to help them determine how best they can fit into the market and develop from ideas to Series A. He is also an advisor and a core member of the Life Sciences Advisory Council to the SWAN Impact Network, one of the most prominent impact angel networks in the United States.
Besides his private practice, Dr. Cui is also an active contributor to the academia. While working in Hong Kong as a registered foreign lawyer, he served as an adjunct faculty member at The Chinese University of Hong Kong Faculty of Law for three years, where he taught the course on Principles of Intellectual Property and established the course on Chinese IP Law. He is a frequent guest lecturer and panelist at top universities and law schools in the United States and in China on IP protection and technology transactions.
Before and while attending law school, Can worked as a U.S. patent agent, focusing on patent prosecution in the life sciences and pharmaceutical industries.
Concentrations
• Life sciences and med-tech licensing, collaboration and strategic partnerships
• Cross-border technology transactions and investments
• International joint ventures
• Asia and China practice
• Intellectual property protection and strategic counseling
Experience
Representative Matters
• A startup focused on the discovery and development of transformative therapies for the unmet medical needs of cancer patients: IP, licensing, and corporate matters.°
• A biopharmaceutical company dedicated to the development of innovative anti-cancer metastasis and antiviral drugs: IP and corporate matters.
• A company developing novel therapeutics based on gene editing, RNA editing, and delivery technology: IP and technology transactions.
• A biotech venture capital positioned to rapidly translate scientific discoveries into innovative new medicines: China licensing matters.°
• A company pioneering transformation of cancer treatment by enabling CAR-T cancer therapies to work more effectively: various licensing and collaboration matters.°
• A medical device company dedicated to ending obesity: China collaboration.°
• A clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies: China IP matters.°
• A biotechnology company developing antibody drug conjugates: China licensing dispute resolution.°
• A privately owned medical device company based in Silicon Valley, California, USA: China licensing matters.°
• A clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer: licensing dispute resolution.°
• A world leader in executing complex cell edits: various licensing transactions.°
• A company developing drugs that specifically target the tumor blood vessels of most solid tumors: corporate restructuring and China licensing matters.°
• A global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide: various technology transactions.°
• The only biotech company in China with publicly declared focus to develop Treg immune therapy: patent, corporate, and technology transactions matters.
• A preclinical stage biotherapeutics company developing cost-effective, non-invasive, and easily accessible technologies to cure lung disease and repair damaged lung tissue: sponsored research agreements.°
• A company discovering life-changing medicines and cures for people with viral and liver diseases: various technology transactions.°
• A medical device company committed to improving the experience of both patients and surgeons through innovative technologies: patent matters.°
• A biomedical company working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, healthier lives: China collaboration.°
• An innovative drug research and development company that focuses on the field of cellular immunotherapy: various licensing matters.°
• A family-owned medical device company that works with physicians to develop devices that are less invasive for patients: China strategies.°
• A company developing and manufacturing proprietary interventional liquid nitrogen spray cryotherapy systems: financing from China.°
• A company developing energy devices for various aesthetic and dermatology treatments: China regulatory matters.°
• A developer of novel, coordinated immunotherapy solutions for patients: various licensing transactions.°
• A developer of custom diagnostic solutions with a focus on large-scale, global diagnostic needs including antibody, molecular, and antigen tests in traditional and non-traditional settings: China supply matters.°
• Eluminex Biosciences: various licensing and collaboration transactions, including:
o global exclusive license agreement with FibroGen, Inc. on biosynthetic cornea and other recombinant human collagen products.°
o acquisition of Zuretinol assets from Retinagenix Holdings.°
• A leader in OLED microdisplay technology for the next generation of computing and imaging devices: China distribution matters.°
• A discovery research company developing revolutionary treatments for patients with genetic disorders: general corporate, asset transfer, financing, and licensing, and services agreements.°
• A developer of EV charging software and hardware for forward-thinking companies around the world: development services agreement.°
• A consumer health and wellness products platform focused on better-for-you consumer health & personal care brands and products: China patent and regulatory matters.°
• A biotech company that drives drug discovery on with AI: IP matters.°
• A pioneering vaccine company dedicated to developing innovative solutions for global health challenges: general corporate matters.°
• A medical research company to improve reproductive health care: China supply matters.°
• A biotechnology company developing innovative gene therapies and cell therapies that are affordable and therapeutically effective: various patent and licensing matters.°
• A developer of a differentiated pipeline of innovative antibody therapeutics that will potentially transform how cancers are treated: general corporate, IP, tax, cybersecurity, licensing, and dispute resolution matters.°
• The first company in China to use induced-pluripotent stem cells and mesenchymal stem cell technology to develop a new generation of universal cell therapy products to treat clinically incurable diseases: licensing and collaboration matters.°
• A global biopharmaceutical company with a focus on oncology, autoimmune diseases, and ophthalmic diseases: licensing and collaboration matters.°
• A medical device company capturing, promoting, and advancing the category of abdominal wall and pelvic floor health, using a multifaceted, gender-specific approach: consulting agreement and various collaboration matters.°
• A biopharmaceutical company engaged in discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases: contract dispute resolution.°
• A biomedical research technology company dedicated to the development and application of tumor immunotherapy technology: licensing and collaboration matters.°
• A cancer therapeutics biotechnology company, located at LabCentral in Cambridge, Massachusetts: China collaboration.°
• A developer of mobile phototherapy systems: general corporate, regulatory, and trademark matters.°
• A global mRNA CDMO company headquartered in United States: patent strategies.°
• A pharmaceutical company developing innovative products of low regulatory risks and high market potentials: financing and regulatory matters.°
• A leading eClinical provider: China human genetic resources regulatory advice.°
• A bio-pharma company spun out from Stanford University and focusing on developing new therapeutics based on innovative drug delivery technologies to address unmet medical needs of human and companion animals: IP and technology transactions.°
• A biotechnology company specializing in the development of advanced therapeutic antibodies, particularly focused on neurodegenerative diseases such as Alzheimer's disease: general corporate matters.°
• A next-generation biotech company specializing in computational drug design for innovative therapeutics: IP and licensing matters.°
• A company that has nearly $10 billion in public equities, primarily in the technology sector: China IP due diligence.°
• A pharmaceutical company using cutting-edge tools to make therapeutic progress against the most challenging of targets: sale of a subsidiary.°
• A strategy software provider: IP matters.°
• A private, Canada-based biotech company focused on neuroscience therapeutics: technology transactions.°
• A high-tech biopharmaceutical enterprise that is dedicated to advancing global innovation in the discovery of new peptide drugs: various collaborations.°
• A company developing non-degrading molecular glues to tackle difficult drug targets to improve patient outcomes: various collaborations.°
• A biotechnology company headquartered in China’s Eye Valley: various licensing and collaboration matters.°
• A health care company pioneering the field of integrated diagnostics: China contract dispute resolution and subsidiary China data transfer matters.°
• A leading Chinese company in gene therapies based on gene editing: IP, licensing, and financing matters.°
• A company specializing in international investment and financing, market access consulting, import-export trade, market promotion, sales, production outsourcing, and global procurement services in the biopharmaceutical and medical device industries: general corporate matters.°
• A company that pioneers innovative therapies for cancer, genetic diseases, and autoimmune diseases: IP and various licensing and collaboration matters.°
• A leading antibody discovery service provider with a pioneering platform that can accelerate the process and capture all available data: general corporate and IP matters.°
• A pioneer in discovering the mRNA-dependent DNA repair pathway and developing next-gen treatment for cancer treatment: general corporate, financing, and collaboration matters.°
• A provider of a single integrated cloud-based management console: China IP dispute resolution matters.°
• A China-based, global-oriented R&D company focusing on innovative drugs for diseases in the field of nervous system and autoimmunity: various licensing and collaboration matters.°
• A high-tech biotechnology company co-founded by overseas experts, returnee scientists and local Chinese pharmaceutical entrepreneurs: various licensing, collaboration and financing matters, including collaboration with and investment by a global, science-led, patient-focused pharmaceutical company.°
• A privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival: general corporate, IP, and licensing matters.°
• A biologically-targeted radiation therapy company focused on developing novel treatment to improve the lives of patients with difficult-to-treat cancers: various distribution, license, and collaboration transactions, including with South Korean and Japanese collaborators.°
• A rapidly developing company primarily engaged in the production of heat sinks, fans, and related products: IP matters.°
• A company engaged in research, development, therapeutic trials, creation, production, operation, marketing, distribution of therapeutic products for the treatment of cancer: general corporate and collaboration matters.°
• A company developing a technology that combines the noninvasive diffuse reflectance spectroscopy with patented algorithms for detecting various skin properties and body health condition: various licensing transactions.°
• A company active in the field of research, development, therapeutic trials, creation, production, operation, marketing, distribution of therapeutic products for the treatment of cancer: general corporate and licensing matters.°
• A company developing multiple new medical technologies to treat various metabolic diseases, such as obesity, type 2 diabetes, and nonalcoholic fatty liver: collaboration matters.°
• Vazyme Biotech Co., Ltd: IP transactions and product distribution matters.°
• A company focused on R&D of innovative mRNA drugs and adjuvants: patent, technology transactions, and global trade matters.°
• A company building computer aided diagnosis algorithms and systems in clinical imaging to improve diagnostic accuracy and effectiveness: various distribution and collaboration matters.°
• A technology innovator with an integrated platform that accelerates biopharmaceutical research: collaboration matters.°
• A provider of new drug candidates through structure-based de novo drug design to accelerate drug discovery: various licensing and collaboration matters.°
• A Chinese national high-tech enterprise specializing in the research and industrialization of innovative drugs: various IP and technology transactions matters.°
°The above representations were handled by Dr. Cui prior to his joining Greenberg Traurig, LLP.
Teaching Experience
• Adjunct Faculty Member, The Chinese University of Hong Kong Faculty of Law, 2013-2016.
• Guest Lecturer, Santa Clara University School of Law, 2022-present.
Recognition & Leadership
Awards & Accolades
• Listed, The Best Lawyers in America, "Ones to Watch," Technology Law, 2024
• Listed, The Legal 500 United States, Life Sciences, 2022-2023
Professional & Community Involvement
• Member, The BayHelix Group, 2021-present
• Lifetime Member, Chinese Bioscience Association, 2021-present
• Lifetime Member, Sino-American Pharmaceutical Professionals Association, 2023-present
